KRISTI LEBESCO: Open Payments
NPI 1386279172 · DANA POINT, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,615 in 142 payments from 18 companies in 2025. Trend: 2023 $1,172 · 2024 $1,232 · 2025 $2,615
Food & beverage: $2,615
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 25 | $377 |
| Alkermes, Inc. | 16 | $269 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 13 | $256 |
| E.R. Squibb & Sons, L.L.C. | 12 | $252 |
| Vanda Pharmaceuticals Inc. | 12 | $218 |
| ABBVIE INC. | 12 | $206 |
| Axsome Therapeutics, Inc. | 8 | $196 |
| Neurocrine BioSciences, Inc. | 12 | $165 |
| Teva Pharmaceuticals USA, Inc. | 7 | $150 |
| Supernus Pharmaceuticals, Inc. | 7 | $138 |
Products named: REXULTI, ARISTADA, CAPLYTA, COBENFY, VRAYLAR, Auvelity, INGREZZA, FANAPT.
Industry payments across CA — which companies pay providers there.
